BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Millman AJ, Nelson NP, Vellozzi C. Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. Curr Epidemiol Rep. 2017;4:174-185. [PMID: 28785531 DOI: 10.1007/s40471-017-0108-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Sreekumar BK, Taha TY, Ott M. Taking cues from convalescence to improve vaccines against hepatitis C virus. J Clin Invest 2022;132:e161819. [PMID: 35912856 DOI: 10.1172/JCI161819] [Reference Citation Analysis]
2 Imbeth-acosta P, Leal-martínez V, Ramos-clason E, Pájaro-galvis N, Martínez-ávila MC, Almanza-hurtado A, Rodríguez-yanez T, Bermudez-montero J, Vergara-serpa O, Abuabara-franco E, Raad-sarabia M, Villar-gonzález EP, Tatis-geney SI, Collazos-torres LA, Rico-fontalvo J, Daza-arnedo R, Pérez-calvo C, Alvarado-castell H, López Acuña GH. Prevalence of Chronic Infection by Hepatitis C Virus in Asymptomatic Population With Risk Factors in Cartagena, Colombia. Front Med 2022;9:814622. [DOI: 10.3389/fmed.2022.814622] [Reference Citation Analysis]
3 McKay LGA, Thomas J, Albalawi W, Fattaccioli A, Dieu M, Ruggiero A, McKeating JA, Ball JK, Tarr AW, Renard P, Pollakis G, Paxton WA. The HCV Envelope Glycoprotein Down-Modulates NF-κB Signalling and Associates With Stimulation of the Host Endoplasmic Reticulum Stress Pathway. Front Immunol 2022;13:831695. [PMID: 35371105 DOI: 10.3389/fimmu.2022.831695] [Reference Citation Analysis]
4 Butaru AE, Gheonea DI, Rogoveanu I, Diculescu M, Boicea AR, Bunescu M, Streba CT, Oancea CN. Micro-Elimination: Updated Pathway to Global Elimination of Hepatitis C in Small Communities and Industrial Settings during the COVID 19 Pandemic. J Clin Med 2021;10:4976. [PMID: 34768496 DOI: 10.3390/jcm10214976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Abu-Freha N, Wainstock T, Poupko L, Sheiner E. Maternal Hepatitis B or Hepatitis C Virus Carrier Status is Not a Risk Factor for Long-Term Oncologic Morbidity of the Offspring: A Population-Based Cohort Study. Cancer Invest 2021;:1-6. [PMID: 33784229 DOI: 10.1080/07357907.2021.1910704] [Reference Citation Analysis]
6 Wang GP, Schnell GL, Kort JJ, Sidhu GS, Schuster L, Tripathi RL, Larsen L, Michael LC, Bergquist K, Magee A, Patel CB, Whitlock JA, Tamashiro R, Peter JA, Fried MW, Nelson DR. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir. J Hepatol 2021:S0168-8278(21)00339-1. [PMID: 34023351 DOI: 10.1016/j.jhep.2021.04.057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Myers D, McVaney B, Higginbotham Z. A case of disseminated cryptococcus in an immunocompetent individual necessitating ventriculoperitoneal shunt. Med Mycol Case Rep 2021;32:53-5. [PMID: 33898212 DOI: 10.1016/j.mmcr.2021.03.001] [Reference Citation Analysis]
8 Rajabi A, Sharafi H, Alavian SM. Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis. Harm Reduct J 2021;18:12. [PMID: 33482831 DOI: 10.1186/s12954-020-00441-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M; TAP study group. Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study. Int J Drug Policy 2021;87:102983. [PMID: 33126166 DOI: 10.1016/j.drugpo.2020.102983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Siddiqui M, Manansala JS, Abdulrahman HA, Nasrallah GK, Smatti MK, Younes N, Althani AA, Yassine HM. Immune Modulatory Effects of Vitamin D on Viral Infections. Nutrients 2020;12:E2879. [PMID: 32967126 DOI: 10.3390/nu12092879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
11 Ponvilawan B, Charoenngam N, Rujirachun P, Wattanachayakul P, Tornsatitkul S, Rittiphairoj T, Ungprasert P. Chronic Hepatitis C Virus Infection is Associated with an Increased Risk of Lung Cancer: A Systematic Review and Meta-analysis. Lung 2020;198:705-14. [DOI: 10.1007/s00408-020-00365-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Carvalho-Louro DM, Soares EB, Trevizoli JE, Marra TMG, da Cunha ALR, Rodrigues MP, Carvalho-Furtado ACL, Dos Santos BTA, de Assis da Rocha Neves F. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil. BMC Infect Dis 2020;20:114. [PMID: 32041537 DOI: 10.1186/s12879-020-4809-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Behzadifar M, Behzadifar M, Bragazzi NL. A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran. BMC Public Health 2020;20:62. [PMID: 31937278 DOI: 10.1186/s12889-020-8175-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ramdas V, Talwar R, Banerjee M, Joshi AA, Das AK, Walke DS, Borhade P, Dhayagude U, Loriya R, Gote G, Bommakanti A, Sivaram A, Agarwal G, Goswami A, Nigade P, Mehta M, Patil V, Modi D, Kumar H, Mallurwar S, Dash A, Modi F, Kuldharan S, Srivastava P, Singh M, Narasimham L, Gundu J, Sharma S, Kamboj RK, Palle VP. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. J Med Chem 2019;62:10563-82. [PMID: 31710479 DOI: 10.1021/acs.jmedchem.9b01562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Miller LS, Millman AJ, Lom J, Osinubi A, Ahmed F, Dupont S, Rein D, Vellozzi C, Harris AM. Defining the hepatitis C cure cascade in an Urban health system using the electronic health record. J Viral Hepat 2020;27:13-9. [PMID: 31505088 DOI: 10.1111/jvh.13199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
16 Zhou B, Cai GFF, Lv HKK, Xu SFF, Wang ZTT, Jiang ZGG, Hu CGG, Chen YDD. Factors Correlating to the Development of Hepatitis C Virus Infection among Drug Users-Findings from a Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2019;16:E2345. [PMID: 31269774 DOI: 10.3390/ijerph16132345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Elad S, Zadik Y, Caton JG, Epstein JB. Oral mucosal changes associated with primary diseases in other body systems. Periodontol 2000 2019;80:28-48. [DOI: 10.1111/prd.12265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
18 Ijaz B, Ahmad W, Das T, Shabbiri K, Husnain T, Hassan S. HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers. Genes Dis 2019;6:304-17. [PMID: 32042870 DOI: 10.1016/j.gendis.2019.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Assoumou L, Thormann F, Soulié C, Caby F, Dudoit Y, Marcelin AG, Goudot P, Blanc C, Coriat P, Katlama C, Costagliola D, Pourcher V. Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery. HIV Med 2019;20:353-8. [PMID: 30924598 DOI: 10.1111/hiv.12732] [Reference Citation Analysis]
20 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut 2018;67:2025-34. [PMID: 29703790 DOI: 10.1136/gutjnl-2018-316234] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 19.8] [Reference Citation Analysis]
22 Ravaioli F, Colecchia A, Dajti E, Marasco G, Alemanni LV, Tamè M, Azzaroli F, Brillanti S, Mazzella G, Festi D. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. World J Hepatol 2018; 10(10): 731-742 [PMID: 30386466 DOI: 10.4254/wjh.v10.i10.731] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
23 Sherbuk JE, McManus KA, Rogawski McQuade ET, Knick T, Henry Z, Dillingham R. Hepatitis C Within a Single Health System: Progression Along the Cascade to Cure Is Higher for Those With Substance Misuse When Linked to a Clinic With Embedded Support Services. Open Forum Infect Dis 2018;5:ofy202. [PMID: 30255113 DOI: 10.1093/ofid/ofy202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
24 Espinosa C, Jhaveri R, Barritt AS 4th. Unique Challenges of Hepatitis C in Infants, Children, and Adolescents. Clin Ther 2018;40:1299-307. [PMID: 30107999 DOI: 10.1016/j.clinthera.2018.07.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
25 Zhang ZH, Jiang BC, Liu XH, Zhang MX, Li ZS, Zhu GZ. Interleukin-7 Regulates T Follicular Helper Cell Function in Patients with Chronic Hepatitis C. Viral Immunol 2018;31:417-25. [PMID: 29672235 DOI: 10.1089/vim.2018.0010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
26 Espinosa CM, Jhaveri R. Update on the management of hepatitis B and C infections in the neonatal period. Semin Perinatol 2018;42:185-90. [PMID: 29526383 DOI: 10.1053/j.semperi.2018.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Maughan A, Ogbuagu O. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol 2018;14:219-27. [PMID: 29271660 DOI: 10.1080/17425255.2018.1421173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
28 Briggs AL. Pharmacists' increasing involvement in hepatitis C management and prevention. Journal of the American Pharmacists Association 2018;58:5-6. [DOI: 10.1016/j.japh.2017.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]